145 related articles for article (PubMed ID: 2858256)
1. Huntington's disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes.
Marshall PE; Landis DM
Brain Res; 1985 Mar; 329(1-2):71-82. PubMed ID: 2858256
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
Marshall PE; Landis DM; Zalneraitis EL
Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
[TBL] [Abstract][Full Text] [Related]
3. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia.
Albin RL; Reiner A; Anderson KD; Penney JB; Young AB
Ann Neurol; 1990 Apr; 27(4):357-65. PubMed ID: 1972318
[TBL] [Abstract][Full Text] [Related]
4. Distribution of somatostatin immunoreactivity in the forebrain of the squirrel monkey: basal ganglia and amygdala.
Desjardins C; Parent A
Neuroscience; 1992; 47(1):115-33. PubMed ID: 1349731
[TBL] [Abstract][Full Text] [Related]
5. Extrahypothalamic vasopressin is unchanged in Parkinson's disease and Huntington's disease.
Rossor MN; Hunt SP; Iversen LL; Bannister R; Hawthorn J; Ang VT; Jenkins JS
Brain Res; 1982 Dec; 253(1-2):341-3. PubMed ID: 6217862
[TBL] [Abstract][Full Text] [Related]
6. Compartmental loss of NADPH diaphorase in the neuropil of the human striatum in Huntington's disease.
Morton AJ; Nicholson LF; Faull RL
Neuroscience; 1993 Mar; 53(1):159-68. PubMed ID: 7682296
[TBL] [Abstract][Full Text] [Related]
7. The distribution of substance P in the primate basal ganglia: an immunohistochemical study of baboon and human brain.
Beach TG; McGeer EG
Neuroscience; 1984 Sep; 13(1):29-52. PubMed ID: 6208509
[TBL] [Abstract][Full Text] [Related]
8. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.
Glass M; Faull RL; Dragunow M
Neuroscience; 1993 Oct; 56(3):523-7. PubMed ID: 8255419
[TBL] [Abstract][Full Text] [Related]
9. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
10. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus.
Richfield EK; Herkenham M
Ann Neurol; 1994 Oct; 36(4):577-84. PubMed ID: 7944290
[TBL] [Abstract][Full Text] [Related]
11. Acidic and basic fibroblast growth factor-like immunoreactivity in the striatum and midbrain in Huntington's disease.
Tooyama I; Kremer HP; Hayden MR; Kimura H; McGeer EG; McGeer PL
Brain Res; 1993 Apr; 610(1):1-7. PubMed ID: 7686078
[TBL] [Abstract][Full Text] [Related]
12. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease.
Norris PJ; Waldvogel HJ; Faull RL; Love DR; Emson PC
Neuroscience; 1996 Jun; 72(4):1037-47. PubMed ID: 8735228
[TBL] [Abstract][Full Text] [Related]
13. Substance P and substance P receptor histochemistry in human neurodegenerative diseases.
Kowall NW; Quigley BJ; Krause JE; Lu F; Kosofsky BE; Ferrante RJ
Regul Pept; 1993 Jul; 46(1-2):174-85. PubMed ID: 7692486
[TBL] [Abstract][Full Text] [Related]
14. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.
Perry TL; Hansen S; Kloster M
N Engl J Med; 1973 Feb; 288(7):337-42. PubMed ID: 4345566
[No Abstract] [Full Text] [Related]
15. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.
Dawbarn D; De Quidt ME; Emson PC
Brain Res; 1985 Aug; 340(2):251-60. PubMed ID: 2862959
[TBL] [Abstract][Full Text] [Related]
16. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ
Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898
[TBL] [Abstract][Full Text] [Related]
17. Some remarks concerning the possible role of brain monoamines (dopamine, noradrenaline, serotonin) in mental disorders.
Hornykiewicz O
J Psychiatr Res; 1974; 11():249-53. PubMed ID: 4282386
[No Abstract] [Full Text] [Related]
18. Calbindin D28K as a marker for the degeneration of the striatonigral pathway in Huntington's disease.
Kiyama H; Seto-Ohshima A; Emson PC
Brain Res; 1990 Aug; 525(2):209-14. PubMed ID: 2147568
[TBL] [Abstract][Full Text] [Related]
19. Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington's disease.
Sun Z; Del Mar N; Meade C; Goldowitz D; Reiner A
Neurobiol Dis; 2002 Dec; 11(3):369-85. PubMed ID: 12586547
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
Allen KL; Waldvogel HJ; Glass M; Faull RL
J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
